Company intelligence / Profile preview

Allerbio

Ownership: Private
Development stage: Commercial

Overview

Allerbio offers clinically proven products that reduce the frequency and severity of various types of allergies by controlling IgE levels and regulating allergen-specific immune responses.

Therapeutic areas: Immunology
Modalities: Probiotics
Industry: Biotech

Drug pipeline

1 asset

AllerBio

Commercial

Indications: Allergic rhinitis, Allergic bronchitis, Allergic asthma, Atopic dermatitis, Seasonal allergies

Beyond the preview

Go deeper on Allerbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allerbio.

Explore the full profile